Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 3/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.49 |
| ▸ | SMYD3 | Q9H7B4 | 5/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | KHK | P50053 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21775966 | 0.92 | CBLB (0.48) | ROCK2ROCK1NPC1RAB9ADRD4 | |
| SCHEMBL12026594 | 0.90 | ROCK2 (0.59) | ROCK2ROCK1NPC1RAB9ASMYD3 | |
| SCHEMBL14441170 | 0.87 | RAB9A (0.65) | ROCK2ROCK1NPC1RAB9AL3MBTL1 | |
| SCHEMBL24726480 | 0.86 | RAB9A (0.68) | ROCK2ROCK1NPC1RAB9AL3MBTL1 | |
| SCHEMBL27396502 | 0.86 | RAB9A (0.68) | ROCK2ROCK1NPC1RAB9AL3MBTL1 | |
| SCHEMBL25647122 | 0.86 | RAB9A (0.68) | ROCK2ROCK1NPC1RAB9AL3MBTL1 | |
| SCHEMBL12089754 | 0.83 | SMYD3 (0.50) | NPC1RAB9AHTR4SMYD3SMN1; SMN2 | |
| SCHEMBL13130451 | 0.83 | ROCK2 (0.58) | ROCK2ROCK1NPC1RAB9ASMYD3 | |
| SCHEMBL279972 | 0.82 | NPC1 (0.74) | NPC1RAB9ASMYD3L3MBTL1KHK | |
| Hydrochloric Acid SCHEMBL28155978 | 0.81 | NPC1 (0.72) | NPC1RAB9ASMYD3L3MBTL1KHK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10988482-B2 | IRAK4 inhibitor and use thereof | Beijing Hanmi Pharmaceutical Co., Ltd. (CN) | 2021-04-27 | — | — | US | disclosed |
| US-20200062775-A1 | IRAK4 INHIBITOR AND USE THEREOF | Beijing Hanmi Pharmaceutical Co., Ltd. (CN) | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10988482-B2 | IRAK4 inhibitor and use thereof | IRAK4, IRAK1, IRAK2 | ROCK2 1641/4885ROCK1 1160/4885NPC1 1555/4885 |
| US-20200062775-A1 | IRAK4 INHIBITOR AND USE THEREOF | IRAK4, IRAK1, IRAK2 | ROCK2 1641/4885ROCK1 1160/4885NPC1 1555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.